Category Archives for "Cancer Drugs"

JAK Mutations a Possible Indicator of Drug Resistance

JAK mutations

JAK Mutations are genetic abnormalities that affect the production of red blood cells. They are often found in individuals with polycythemia vera, as well as a number of other myeloproliferative neoplasms. The anti-PD-1 agent, Keytruda (pembrolizumab) was approved in 2014 by the U.S. Food and Drug Administration for the treatment of advanced melanoma. Since then, it has received […]

Continue reading

European Committee Approves Opdivo Advance


Opdivo Advances in Europe In response to the decision made in the United States last March, manufacturer Bristol-Myers Squibb has announced a new dosing schedule for Opdivo (nivolumab), recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency. This new dosing schedule lets physicians choose to prescribe Opdivo as a […]

Continue reading

CHIPSA Hospital Files Patent on Cancer Immunotherapy Combination of Checkpoint Inhibitors and Coley Vaccine

Preclinical and Clinical Data Support Efficacy of Novel Approach to Cancer Immunotherapy Developed by CHIPSA Hospital CHIPSA Hospital, dedicated to the accelerated development of nontoxic cancer immunotherapies announced today filing of a patent application covering the combination of FDA approved antibodies known as “checkpoint inhibitors” together with Coley Vaccine, a stimulatory of innate immunity. CHIPSA […]

Continue reading

Steep Rise in Prices of Older Cancer Drugs

Prices of Older Cancer Drugs

The study included oral and intravenous chemotherapy cancer drugs covered by Medicare Part B. Medicare is the federal health insurance plan for people 65 or older. “Higher costs lead to higher copays,” said study co-author Dr. Sham Mailankody. He’s a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City. “And empiric research […]

Continue reading